DiCE Molecules Holding LLC

DiCE Therapeutics, Inc. is a biopharmaceutical company. It designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company was founded by J. Kevin Judice on August 14, 2013 and is headquartered in South San Francisco, CA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DiCE Therapeutics, Inc. is a biopharmaceutical company, which designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company was founded by J. Kevin Judice on August 14, 2013 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. All of the shares of common stock are being offered by DICE. In addition, DICE intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

DICE Announces Proposed Public Offering of Common Stock

Coinbase

One of these companies is a leader in its niche, while the other wants to become one.

Nasdaq Bear Market: 2 Stocks Defying the Downturn

Source: Olga Kononok/Shutterstock Dice Therapeutics (NASDAQ: DICE ) stock is up about 50% today on reports that the biotechnology company achieved positive Phase 1 clinical trial results for its psoriasis treatment. Jumping significantly in premarket trading this morning, the kind of movement we're seeing from shares today is an incredible feat for any stock.

What Is Going on With DICE Therapeutics (DICE) Stock?

Dice stock skyrocketed to a record high Tuesday after the biotech company unveiled promising early-stage test results for a psoriasis pill. The post Dice Therapeutics Surges To Record High As Psoriasis Pill Promises To Lead Its Class appeared first on Investor's Business Daily.

Dice Therapeutics Surges To Record High As Psoriasis Pill Promises To Lead Its Class

Shares of Dice Therapeutics Inc. soared 88.8% in premarket trading on Monday after the company shared promising Phase 1 data for its experimental psoriasis treatment. Dice said the investigational oral therapy was well-tolerated and showed a mean percentage reduction in the Psoriasis Area and Severity Index.

Dice's stock jumps 88%; the company plans to submit its psoriasis treatment candidate to the FDA next year

Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group compared to 13.3% in the placebo group, with an exploratory p-value of 0.0008

DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today reported financial results and business highlights for the second quarter ended June 30, 2022.

DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent Highlights

DICE Therapeutics (DICE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for DICE Therapeutics (DICE)

Absci Corp

Axcella Health Inc

Freeline Therapeutics Holdings

 Pliant Therapeutics

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the completion of enrollment in the Company's Phase 1 clinical trial of DC-806 in healthy volunteers and psoriasis patients. DC-806 is an orally-available, small molecule antagonist of the pro-inflammatory cytokine, interleukin-17 (IL-17), which is a validated drug target for the treatment of a variety of autoimmune and inflammatory diseases, including psoriasis.

DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:30 p.m. ET.

DICE Therapeutics to Present at the 2022 Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today reported financial results and business highlights for the first quarter ended March 31, 2022.

DICE Therapeutics Reports First Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will present at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 1:20 p.m. PT / 4:20 p.m. ET.

DICE Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the appointment of Mary Riley as general counsel and the additions of Lisa Bowers and Mittie Doyle, M.D., FACR, to DICE's board of directors. Concurrently, Stephen Zachary, Ph.D., will be stepping down from the Company's board.

DICE Therapeutics Expands Management Team and Board of Directors

SOUTH SAN FRANCISCO, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2021.

DICE Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 at 4:20 p.m. ET.

DICE Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will participate in the following investor conferences in November:

DICE Therapeutics to Present at November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today reported financial results and business highlights for the third quarter ended September 30, 2021.

DICE Therapeutics Reports Third Quarter 2021 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that the first healthy volunteer has been dosed in the Company's Phase 1 clinical trial of S011806. S011806 is an orally-available, small molecule antagonist of the pro-inflammatory cytokine, interleukin-17 (IL-17), which is a validated drug target for the treatment of a variety of immunological diseases. The Phase 1 trial of S011806 is designed to generate safety and pharmacokinetic data, as well as provide early clinical proof-of-concept in psoriasis patients.

News for DiCE Molecules Holding LLC Stock (DICE)